Paul A. Mahon, serving as Executive Vice President and General Counsel for United Therapeutics Corp (NASDAQ:UTHR), executed a significant divestment of company equity on June 4, 2026. According to regulatory filings, Mahon sold a total of 8,300 shares of the firm's common stock. The transaction generated approximately $4.54 million in proceeds and was structured under a pre-arranged 10b5-1 trading plan, which is designed to allow insiders to trade company stock without violating insider trading laws.
Before executing the sale, Mahon exercised 8,300 stock options, acquiring the common stock at a strike price of $146.03 per share. The total value associated with the acquisition of these shares through option exercise amounted to $1,212,049. The subsequent sale of the 8,300 shares occurred at prices ranging from $539.76 to $549.4948 per share. The filing indicates that these sales were executed through multiple trades, with the reported prices representing weighted averages. The total proceeds from the sale reached $4,540,642. Following these transactions, Mahon directly holds 45,172 shares of United Therapeutics common stock.
The insider transaction occurs as United Therapeutics shares trade at $547.69, a level near their 52-week high of $609.35. This price point follows a remarkable 69.61% gain over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate. The company maintains impressive gross profit margins of 86.58% and holds more cash than debt on its balance sheet, according to InvestingPro Tips.
In recent corporate developments, United Therapeutics Corporation reported first-quarter revenue of $781.5 million, which fell short of the analyst consensus estimate of $797.4 million. The company’s Tyvaso revenues were $457.5 million, also missing the expected $478.6 million. Net income for the quarter was $274.9 million, compared to the consensus estimate of $320.5 million. Despite these results, TD Cowen reiterated its Buy rating for United Therapeutics, maintaining a price target of $675.00. Additionally, BTIG reiterated a Neutral rating following the earnings report.
United Therapeutics announced that its TETON-1 phase 3 study of nebulized Tyvaso in idiopathic pulmonary fibrosis met its primary endpoint, with findings published in the New England Journal of Medicine. The study showed that Tyvaso preserved lung function and reduced the risk of clinical worsening events. In a separate development, United Therapeutics partnered with Varda Space Industries to explore microgravity-based pharmaceutical processing for rare pulmonary diseases. The collaboration aims to improve the stability, bioavailability, and delivery characteristics of therapeutic compounds.